Gene · 2348
Papers3,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 3,253
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PROTAC-based protein degradation: a window of opportunity for melanoma therapy. | J Biomed Sci | 2026 | 41761284 | PubTator, text mining | PubMed |
| Corrigendum to "performance of the VENTANA FOLR1 assay for folate receptor alpha: Real-world evidence from 313 Chinese participants" pathology - research and practice 279 (2026) 156359. | Pathol Res Pract | 2026 | 41760500 | PubTator, text mining | PubMed |
| Clinicopathologic and prognostic significance of FOLR1 expression in gastric adenocarcinoma and its association with PD-L1, HER2, MMR, and p53 status. | Virchows Arch | 2026 | 41758267 | PubTator, text mining | PubMed |
| Harnessing Folate-Mediated PSMA Targeting for Precision Therapy: An Intelligent Liposomal Nanoplatform Against Prostate Cancer. | Pharmaceutics | 2026 | 41754985 | PubTator, text mining | PubMed |
| Frontiers in Antibody-Drug Conjugates: Mechanisms, Design Innovations, and Clinical Applications in Targeted Cancer Therapy. | Pharmaceuticals (Basel) | 2026 | 41754865 | PubTator, text mining | PubMed |
| Folate Status Shaped by Taste Receptor Genetics and Sociobehavioral Modulation: Evidence from a Hungarian Cohort. | Nutrients | 2026 | 41754079 | PubTator, text mining | PubMed |
| Expression Profile of Metabotropic Glutamate Receptors in Lung Adenocarcinoma: GRM5 and Validation of Its Targeting Drug Cinchonine. | Int J Mol Sci | 2026 | 41751933 | PubTator, text mining | PubMed |
| Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status. | Int J Mol Sci | 2026 | 41751910 | PubTator, text mining | PubMed |
| From Image-Guided Surgery to Computer-Assisted Real-Time Diagnosis with Hyperspectral and Multispectral Imaging: A Systematic Review in Gynecologic Oncology. | Diagnostics (Basel) | 2026 | 41750768 | PubTator, text mining | PubMed |
| Advances in Next-Generation Immunotherapies for Ovarian Cancer: Mechanisms of Immune Evasion and Novel Therapeutic Targets. | Biomolecules | 2026 | 41750317 | PubTator, text mining | PubMed |
| A Phase 1 Dose Escalation of Lapatinib and Paclitaxel in Recurrent Ovarian Cancer. | Cancers (Basel) | 2026 | 41749879 | PubTator, text mining | PubMed |
| Myoclonus in Pediatric Metabolic Diseases: Clinical Spectrum, Mechanisms, and Treatable Causes-A Systematic Review. | Metabolites | 2026 | 41745581 | PubTator, text mining | PubMed |
| Engineering Bi-Specific CAR-NK Cells to Restore Antibody-Dependent Cellular Cytotoxicity in Solid Tumors. | Cells | 2026 | 41744817 | PubTator, text mining | PubMed |
| ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer. | ESMO Open | 2026 | 41741111 | PubTator, text mining | PubMed |
| Maternal-fetal transfer of emerging bisphenols: Exposure profile and potential link to latrogenic preterm birth. | Environ Toxicol Pharmacol | 2026 | 41720368 | PubTator, text mining | PubMed |
Folate receptor-α targeted delivery of berberine via folate-functionalized bovine serum albumin nanocarriers to enhance intracellular internalization and suppress 3D spheroid formation as a pioneering therapeutic modality for glioblastoma. | J Mater Chem B | 2026 | 41686123 | PubTator, text mining | PubMed |
| Heterogeneous graph neural networks reveal molecular mechanisms of folate deficiency in placental insufficiency through multiomics integration. | Sci Rep | 2026 | 41673068 | PubTator, text mining | PubMed |
| Oncolytic viruses: advanced strategies in cancer therapy. | Signal Transduct Target Ther | 2026 | 41639062 | PubTator, text mining | PubMed |
| FOLR1 Mediated by ITCH Promotes Paclitaxel Resistance by Suppressing Pyroptosis in Nasopharyngeal Carcinoma. | Arch Pharm (Weinheim) | 2026 | 41635097 | PubTator, text mining | PubMed |
| Folate receptor 1 activation suppresses high glucose-induced amyloidogenesis in neurons via STAT3/Nrf2 pathway-dependent mitigation of mitochondrial oxidative stress. | Biomed Pharmacother | 2026 | 41633894 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2348/papers?page=7